NewcelX Ltd. files Form D for private placement raising $2.94 million
The Switzerland-based biotech, previously known as NLS Pharmaceutics Ltd., reported completing an equity and warrant offering to five investors.
NewcelX Ltd. filed a Form D notice with the Securities and Exchange Commission, dated as signed on 2026-08-24 by Chief Executive Officer Ronen Twito. The company is incorporated in Switzerland.1 The filing lists a previous name of NLS Pharmaceutics Ltd.1
The company is based in Kloten, Switzerland.1 Its industry classification is listed as Biotechnology1 under the Health Care category.
According to the filing, the date of first sale was 2026-07-031, and the offering was marked as new rather than an amendment. The company said it intends the offering to last more than one year.1
The securities offered consisted of common shares and warrants to purchase common shares, along with options or other rights to acquire additional securities.1 The filing states this was not made in connection with a business combination transaction such as a merger or acquisition.1
On amounts, the filing reports a total offering amount of $2,940,234, with the same amount sold and $0 remaining to be sold, including the exercise price of common shares underlying warrants at an exercise price of $4.437.1 The company said a total of five investors have already invested in the offering.1
No sales commissions or finder's fees were reported, as both figures were listed at $0.1 The filing was made under the exemption claimed as Rule 506(b).1 The document lists company officers and directors including Twito, Michel Revel, Kfir Molakandov, Omri Hagai, and others as related persons in the offering.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.